Search results
Despite currently being unprofitable, Relief Therapeutics Holding (VTX:RLF) has delivered a 644%...
Simply Wall St. via Yahoo Finance· 1 year agoRelief Therapeutics Holding AG (VTX:RLF) shareholders have seen the share price descend 16% over the...
Acer (ACER) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoWe expect investors to focus on updates of Acer Therapeutics’ ACER pipeline and revenue guidance for...
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Zacks via Yahoo Finance· 2 years agoAxsome AXSM announced the enrollment of the first patient in the EMERGE phase III open label study...
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
Zacks via Yahoo Finance· 2 years agoPacira BioSciences, Inc. PCRX reported second-quarter 2022 adjusted earnings of 51 cents per share,...
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
Zacks via Yahoo Finance· 1 year agoPanbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate...
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Zacks via Yahoo Finance· 12 months agoPacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label...
2 Brilliant Growth Stocks to Invest $2,000 in Right Now
Motley Fool· 7 months agoInvestor Ben Graham -- mentor to the Oracle of Omaha himself, Warren Buffett -- was once quoted as...
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
Zacks via Yahoo Finance· 12 months agoAbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of...
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
Zacks via Yahoo Finance· 5 months agoVertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on...
Danaher (DHR) Gears Up to Post Q4 Earnings: Is a Beat in Store?
Zacks via Yahoo Finance· 4 months agoDanaher's (DHR) Q4 earnings are likely to have been hurt by weakness in the Biotechnology and...